These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30668192)

  • 21. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Obinutuzumab for the treatment of lymphoproliferative disorders.
    Owen C; Stewart DA
    Expert Opin Biol Ther; 2012 Mar; 12(3):343-51. PubMed ID: 22283718
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Obinutuzumab for B-cell malignancies.
    Owen CJ; Stewart DA
    Expert Opin Biol Ther; 2014 Aug; 14(8):1197-205. PubMed ID: 24856933
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Population pharmacokinetics and CD20 binding dynamics for mosunetuzumab in relapsed/refractory B-cell non-Hodgkin lymphoma.
    Bender B; Li CC; Marchand M; Turner DC; Li F; Vadhavkar S; Wang B; Deng R; Lu J; Jin J; Li C; Yin S; Wei M; Chanu P
    Clin Transl Sci; 2024 Jun; 17(6):e13825. PubMed ID: 38808543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Obinutuzumab in chronic lymphocytic leukemia: design, development and place in therapy.
    Al-Sawaf O; Fischer K; Engelke A; Pflug N; Hallek M; Goede V
    Drug Des Devel Ther; 2017; 11():295-304. PubMed ID: 28182141
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions.
    Goede V; Fischer K; Busch R; Engelke A; Eichhorst B; Wendtner CM; Chagorova T; de la Serna J; Dilhuydy MS; Illmer T; Opat S; Owen CJ; Samoylova O; Kreuzer KA; Stilgenbauer S; Döhner H; Langerak AW; Ritgen M; Kneba M; Asikanius E; Humphrey K; Wenger M; Hallek M
    N Engl J Med; 2014 Mar; 370(12):1101-10. PubMed ID: 24401022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical application of obinutuzumab for treating chronic lymphocytic leukemia.
    Luan C; Chen B
    Drug Des Devel Ther; 2019; 13():2899-2909. PubMed ID: 31692500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pertuzumab in HER2-positive early breast cancer: current use and perspectives.
    Eiger D; Pondé NF; de Azambuja E
    Future Oncol; 2019 Jun; 15(16):1823-1843. PubMed ID: 30938542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.
    Freeman CL; Dixon M; Houghton R; Kreuzer KA; Fingerle-Rowson G; Herling M; Humphrey K; Böttcher S; de Costa CS; Iglesias V; Stilgenbauer S; Gribben J; Hallek M; Goede V
    Leukemia; 2016 Aug; 30(8):1763-6. PubMed ID: 26979130
    [No Abstract]   [Full Text] [Related]  

  • 30. Management of patients with previously untreated chronic lymphocytic leukaemia with obinutuzumab and chlorambucil.
    Tam C; Kuss B; Opat S; Boulos J; Marlton P
    Intern Med J; 2017 Jul; 47 Suppl 4():5-10. PubMed ID: 28685928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Obinutuzumab for the treatment of indolent lymphoma.
    Edelmann J; Gribben JG
    Future Oncol; 2016 Aug; 12(15):1769-81. PubMed ID: 27117452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
    Davies A; Kater AP; Sharman JP; Stilgenbauer S; Vitolo U; Klein C; Parreira J; Salles G
    Future Oncol; 2022 Aug; 18(26):2943-2966. PubMed ID: 35856239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with
    Yoon JT; Longtine MS; Marquez-Nostra BV; Wahl RL
    J Nucl Med; 2018 Aug; 59(8):1219-1224. PubMed ID: 29348316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
    Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
    Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rationale for optimal obinutuzumab/GA101 dosing regimen in B-cell non-Hodgkin lymphoma.
    Cartron G; Hourcade-Potelleret F; Morschhauser F; Salles G; Wenger M; Truppel-Hartmann A; Carlile DJ
    Haematologica; 2016 Feb; 101(2):226-34. PubMed ID: 26659915
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differential regulation patterns of the anti-CD20 antibodies obinutuzumab and rituximab in mantle cell lymphoma.
    Heinrich DA; Weinkauf M; Hutter G; Zimmermann Y; Jurinovic V; Hiddemann W; Dreyling M
    Br J Haematol; 2015 Feb; 168(4):606-10. PubMed ID: 25292485
    [No Abstract]   [Full Text] [Related]  

  • 37. Obinutuzumab: a new class of anti-CD20 monoclonal antibody.
    Gagez AL; Cartron G
    Curr Opin Oncol; 2014 Sep; 26(5):484-91. PubMed ID: 25014645
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies.
    Robak T; Smolewski P; Urbanska-Rys H; Gora-Tybor J; Blonski JZ; Kasznicki M
    Leuk Lymphoma; 2004 May; 45(5):937-44. PubMed ID: 15291352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mogamulizumab for the Treatment of Adult T-cell Leukemia/Lymphoma.
    Ureshino H; Kamachi K; Kimura S
    Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):326-331. PubMed ID: 30981611
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders.
    Castillo J; Milani C; Mendez-Allwood D
    Expert Opin Investig Drugs; 2009 Apr; 18(4):491-500. PubMed ID: 19335277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.